3 AI Healthcare Stocks Retail Investors Are Watching For Growth

With inflation expectations tied to energy prices, shifting central bank policies, and a global push into AI related hardware and software, many investors are looking for themes that do not rely on a single region or macro call. Transformative AI Healthcare brings together two powerful trends: AI adoption and healthcare’s need for better diagnostics, productivity, and remote care. This screener focuses on companies using AI to address real clinical and operational problems, from imaging to drug discovery to virtual care. In this article, you will see 3 of the most compelling stocks filtered by the Transformative AI Healthcare Stocks screener.

ImExHS (ASX:IME)

Overview: ImExHS (ASX:IME) provides cloud based medical imaging software and outsourced radiology services, offering modular systems for radiology, cardiology and pathology, along with teleradiology and diagnostic reporting for hospitals and clinics across multiple countries.

Operations: ImExHS generates about A$10.0 million from Software and A$19.2 million from Radiology (partly offset by A$0.2 million of intersegment eliminations), with all reported revenue of A$29.0 million coming from Latin America.

Market Cap: A$16.8 million

ImExHS stands out in AI powered healthcare because it pairs cloud native imaging software with its own radiology operations, creating a real world test bed for AI tools that aim to cut support costs and speed up reporting. Analysts expect revenue growth to outpace the broader Australian market, with a path sketched out from current losses toward profitability and a higher future return on equity, although those forecasts rely on stronger margins and successful rollout of higher value contracts. The stock currently trades on a low P/S multiple compared with peers, which some investors may see as a sign that expectations are still modest. At the same time, heavy exposure to Latin American healthcare systems, reliance on external borrowing and leadership transition in the CFO role mean the risk side of the story cannot be ignored.

ImExHS pairs low expectations with a cloud based imaging platform that could scale faster than many investors realise, so it is worth reading the analyst forecasts for ImExHS to see what might be missing from the story.

Singular Health Group (ASX:SHG)

Overview: Singular Health Group (ASX:SHG) develops 3DiCom medical software that turns standard 2D scans into interactive 3D models, helping clinicians and patients better visualise anatomy for diagnosis and treatment planning, while also offering secure medical file transfer and cloud based AI tools that integrate with imaging workflows.

Operations: Singular Health Group generates about A$1.0 million in revenue from the provision and development of medical technology, with reported geographic revenue primarily from the United States at approximately A$0.5 million and a segment adjustment of A$0.08 million.

Market Cap: A$68.1 million

Singular Health Group operates at the intersection of 3D imaging and AI, with a focus on turning complex scan data into tools that are easier for clinicians to use and for patients to understand. This aligns with the Transformative AI Healthcare theme. At the same time, revenue is still modest at under A$1 million, the company is loss making with a negative return on equity, and there is less than one year of cash runway funded entirely by higher risk borrowing, so financial risk remains a central consideration. A relatively high P/B multiple and recent share price volatility highlight how sentiment can change quickly, making it important to look past the headline story and focus on the underlying software traction and funding options.

Singular Health Group’s tiny revenue base and sharp share price swings could be masking something more interesting in its 3D imaging and AI story. It is worth reading the analysis report for Singular Health Group to see what investors might be missing.

Artrya (ASX:AYA)

Overview: Artrya (ASX:AYA) is a medical technology company that uses artificial intelligence in its Salix cloud software to assess coronary CT angiography scans, helping clinicians detect and manage coronary artery disease and identify patients at risk of heart attacks.

Operations: Artrya currently generates A$0.03 million in revenue from the development of its AI driven CCTA image analysis technology, all from Australia.

Market Cap: A$907.7 million

Artrya sits at the heart of the Transformative AI Healthcare theme, with AI driven cardiac imaging software, a large planned SAPPHIRE study of 10,000 to 12,000 scans and a three module product suite that targets anatomy, plaque and blood flow in a market where major US insurers already reimburse plaque assessment. At the same time, current revenues are tiny at A$29,000, cash burn is meaningful, the Flow module still needs FDA clearance and competitors such as HeartFlow and Cleerly are already embedded in US hospitals, so execution risk is material. A strong cash position and the appointment of experienced CFO Clayton Hatch give Artrya time to test whether this high growth, high risk proposition can translate its clinical ambition into a scalable business.

Artrya’s tiny revenue and sizeable market cap hint at a story where expectations and execution risk are tightly linked. It is worth reading the analyst forecasts for Artrya to see what could tip the balance.

The three stocks covered here are just a starting point, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener uncovers 5 more companies in this theme with equally compelling AI healthcare narratives. Unlock deeper context and identify your highest conviction ideas by using Simply Wall St to filter for the specific catalysts, cash profiles and AI use cases that matter most to you, so you can analyze which Transformative AI Healthcare stocks best match your approach.

Take Control of Your Investment Journey

If Singular Health Group or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others Do?

Markets move fast and fresh stock ideas do not stay under the radar for long. Spot potential breakouts while it matters, before momentum is fully caught, and act now.

• Target cash rich compounders using the curated 9 high quality undervalued stocks that still sit below many investors' radars yet already pair balance sheet strength with solid cash generation.
• Explore earnings momentum with the focused 63 profitable AI stocks that aren't just burning cash that filters for AI stocks already generating profits instead of just burning through investor capital.
• Zero in on sturdier balance sheets with the pre screened list of solid balance sheet and fundamentals (20 results) so you spend time assessing fundamentals, not worrying about financial fragility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com